$TALK

Talkspace reported Q2 2026 revenue of $61.7M, up 13.6% YoY, with net loss widening to $1.5M and adjusted EBITDA of $1.0M, according to its SEC 10-Q. The company also said it has a pending merger with UHS at $5.25 per share, expected to close in Q3 2026.

Reilly John Charles (Chief Legal Officer, Secretary) sold 40,289 shares of Talkspace, Inc. (TALK) at an average of $5.20 ($5.20–$5.21, $0.21M total) across 3 trades on 2026-06-18.

Reilly John Charles (Chief Legal Officer, Secretary) sold 55,144 shares of Talkspace, Inc. (TALK) at an average of $5.21 ($5.21–$5.22, $0.29M total) across 2 trades on 2026-06-12.

PRISM MarketView highlighted seven public companies developing mental health therapies, devices, and digital platforms during National Mental Health Awareness Month. Featured firms include Helus Pharma (HELP), GH Research (GHRS), AtaiBeckley (ATAI), Definium Therapeutics (DFTX), BrainsWay (BWAY), Neuronetics (STIM), and Talkspace (TALK), spanning psychedelic-derived treatments, TMS, and virtual care.

Talkspace, a digital mental healthcare platform, reported fiscal 2026 Q1 results on May 11 ahead of its planned acquisition by Universal Health Services. The company posted GAAP loss of $0.04 per share (vs. $0.02 expected) and revenue of $61.68 million (up 18.2% YoY, below $64.27 million consensus). Net loss was $6.31 million, including about $7.3 million in one-time merger/advisory costs. Payor revenue rose 28.3% to $48.6 million while D2C revenue fell 26.3% to $3.5 million. Talkspace said it r

Qumra Capital and its affiliates have filed an amended Schedule 13D for Talkspace, Inc. (TALK), revealing a voting agreement that commits their 5% stake to support Talkspace's merger with Universal Health Services. This agreement solidifies Qumra's backing for the transaction, requiring them to vote in favor of the merger and against any alternative proposals. The filing details Qumra's beneficial ownership of Talkspace shares and outlines the terms under which the voting agreement will terminate.

Talkspace (NASDAQ:TALK) shares recently hit a new 52-week high of $5.19 during mid-day trading on Monday, closing at $5.18 on heavy volume. This rise follows a quarterly earnings beat, with the company reporting $0.03 EPS against an estimated $0.02 and revenue of $63.0M. Despite the strong performance, analyst consensus remains a "Hold" with an average target price of $5.56, largely due to several recent downgrades.

The article states that Universal Health Services (UHS) is planning to acquire Talkspace for $5.25 per share. No other details about the acquisition are provided in this truncated content.

Northland Securities has downgraded Talkspace (NASDAQ:TALK) from a "strong-buy" to a "hold" rating, contributing to a consensus "Hold" rating for the stock among analysts with a target price of $5.56. The downgrade coincides with news of UHS's agreement to acquire Talkspace for $5.25 per share, attracting positive sentiment for a clear exit valuation but also sparking lawsuits investigating the fairness of the deal terms. Institutional investors have been adjusting their stakes in Talkspace, with significant purchases and increases in holdings by several firms, while analysts weigh the acquisition's implications and potential litigation risks.

Universal Health Services (UHS) announced its plan to acquire virtual behavioral healthcare provider Talkspace for $5.25 per share, an enterprise value of approximately $835 million. This acquisition will expand UHS's outpatient and telehealth behavioral strategies, aiming to create a nationally scaled, end-to-end continuum in behavioral healthcare, and is expected to be slightly accretive to UHS's adjusted net income per diluted share in the first year. The transaction, unanimously approved by both boards, is anticipated to close in the third quarter of 2026, subject to stockholder and regulatory approvals.